NCT03894085View on ClinicalTrials.gov

Definitive Selection of Neuroimaging Biomarkers in Anxiety Disorder and Obsessive-compulsive Disorder: A Longitudinal Functional Magnetic Resonance Imaging （fMRI） Study With Paroxetine Treatment

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Anxiety DisorderObsessive-Compulsive Disorder
Interventions
DRUG

Paroxetine

Paroxetine treatment for 4 weeks usage:20-80mg Qd

Trial Locations (1)

Unknown

The Second Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Central South University

OTHER

NCT03894085 - Definitive Selection of Neuroimaging Biomarkers in Anxiety Disorder and Obsessive-compulsive Disorder: A Longitudinal Functional Magnetic Resonance Imaging （fMRI） Study With Paroxetine Treatment | Biotech Hunter | Biotech Hunter